Merck & Co., Inc. (NYSE:MRK) Shares Bought by Windward Capital Management Co. CA

Windward Capital Management Co. CA boosted its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 0.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,629 shares of the company’s stock after buying an additional 110 shares during the period. Windward Capital Management Co. CA’s holdings in Merck & Co., Inc. were worth $3,230,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Creative Financial Designs Inc. ADV increased its holdings in Merck & Co., Inc. by 1.9% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 4,811 shares of the company’s stock worth $524,000 after buying an additional 92 shares during the last quarter. Prosperity Financial Group Inc. raised its holdings in shares of Merck & Co., Inc. by 2.9% in the 2nd quarter. Prosperity Financial Group Inc. now owns 3,365 shares of the company’s stock valued at $388,000 after purchasing an additional 95 shares during the period. Bath Savings Trust Co lifted its stake in Merck & Co., Inc. by 1.8% in the 4th quarter. Bath Savings Trust Co now owns 5,539 shares of the company’s stock valued at $604,000 after purchasing an additional 98 shares during the last quarter. King Wealth grew its holdings in Merck & Co., Inc. by 1.3% during the third quarter. King Wealth now owns 7,440 shares of the company’s stock worth $766,000 after purchasing an additional 99 shares during the period. Finally, LifePro Asset Management raised its stake in Merck & Co., Inc. by 1.3% in the third quarter. LifePro Asset Management now owns 7,669 shares of the company’s stock valued at $790,000 after buying an additional 100 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. UBS Group boosted their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $125.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 2nd. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Finally, Barclays upped their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.14.

Read Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $125.32 on Tuesday. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $130.24. The firm has a market capitalization of $317.39 billion, a PE ratio of 895.14, a price-to-earnings-growth ratio of 0.49 and a beta of 0.37. The firm has a fifty day simple moving average of $123.94 and a two-hundred day simple moving average of $112.15. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. The business had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.62 EPS. Analysts forecast that Merck & Co., Inc. will post 8.58 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a dividend of $0.77 per share. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 2.46%. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.